Efficacy and safety of lenvatinib combined with PD‑1/PD‑L1 inhibitors in the treatment of hepatocellular carcinoma: A meta‑analysis and systematic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of lenvatinib combined with PD‑1/PD‑L1 inhibitors in the treatment of hepatocellular carcinoma: A meta‑analysis and systematic review

Published:2024-05-14 Issue:1 Volume:28 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Zhang Baoyan¹,Su Linfeng²,Lin Yonghua³

Affiliation:

1. Department of Pharmacy, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian 362000, P.R. China

2. Department of Hepatobiliary and Pancreatic Surgery, The Second Clinical Medical College of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China

3. Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China

Publisher

Spandidos Publications

Reference28 articles.

1. Management of hepatocellular carcinoma: A review;Brown;JAMA Surg,2023

2. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification;Chidambaranathan-Reghupaty;Adv Cancer Res,2021

3. 2019 update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: The puri II recommendations;Kumar;J Clin Exp Hepatol,2020

4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial;Kudo;Lancet,2018

5. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP